Back to Search Start Over

Data from Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas

Authors :
Gerrit A. Meijer
Remond J.A. Fijneman
Nicole C.T. van Grieken
Veerle M.H. Coupé
Ernst J. Kuipers
Evelien Dekker
Myrthe van Burink
Linda J.W. Bosch
Meike de Wit
Malgorzata A. Komor
Anne S. Bolijn
Jochim S. Terhaar Sive Droste
Begoña Diosdado
Beatriz Carvalho
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

About 5% of colorectal adenomas are estimated to progress to colorectal cancer. However, it is important to identify which adenomas actually carry a high risk of progression, because these serve as intermediate endpoints, for example, in screening programs. In clinical practice, adenomas with a size of ≥10 mm, villous component and/or high-grade dysplasia, called advanced adenomas, are considered high risk, although solid evidence for this classification is lacking. Specific DNA copy number changes are associated with adenoma-to-carcinoma progression. We set out to determine the prevalence of cancer-associated events (CAE) in advanced and nonadvanced adenomas. DNA copy number analysis was performed on archival tissues from three independent series of, in total, 297 adenomas (120 nonadvanced and 177 advanced) using multiplex ligation-dependent probe amplification or low-coverage whole-genome DNA sequencing. Alterations in two or more CAEs were considered to mark adenomas as high risk. Two or more CAEs were overall present in 25% (95% CI, 19.0–31.8) of advanced adenomas; 23% (11/48), 36% (12/33), and 23% (22/96) of the advanced adenomas in series 1, 2, and 3, respectively, and 1.7% (1/58) and 4.8% (3/62) of the nonadvanced adenomas, in series 1 and 2, respectively. The majority of advanced adenomas do not show CAEs, indicating that only a subset of these lesions is to be considered high risk. Nonadvanced adenomas have very low prevalence of CAEs, although those with CAEs should be considered high risk as well. Specific DNA copy number alterations may better reflect the true progression risk than the advanced adenoma phenotype. Cancer Prev Res; 11(7); 403–12. ©2018 AACR.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....35106ae63fdf75de9513b2f07c00c605
Full Text :
https://doi.org/10.1158/1940-6207.c.6547013